logo
Tigerlily relaunches in Australia after two-year break from retail

Tigerlily relaunches in Australia after two-year break from retail

The Australian4 days ago
Australian swimwear and apparel brand Tigerlily is set to make its return to Australian shops this Friday, just in time to celebrate its 25th anniversary.
After a bumpy two-year period, the brand 'all about beach lifestyle' will officially reopen down under.
Customers will be able to purchase Tigerlily's signature bikinis, swimwear, and accessories online and through select retail partners, including department store giant Myer.
Tigerlily general manager Prue Slocombe exclusively told NewWire the brand is looking to bring back its 'personality' back as it returns.
'What we are looking to do with Tigerlily is take it back to that really vibrant, fun personality that it had 10-15 years ago when it was in its prime,' she said.
Ms Slocombe said success for the brand will be built on having a customer first approach and staying authentic to customers.
'From there we would really love to see some aggressive growth. There is absolutely appetite for a considered retail approach.
Iconic Australian retailer Tigerlily will make its return under Seafolly group. Picture Supplied
Iconic Australian retailer Tigerlily will make its return under Seafolly group. Picture Supplied
As part of its anniversary celebrations, the brand will be relaunching some of their best-selling heritage prints.
'When we looked through the archives, it was like kids in a candy store looking at all the prints, so we will be tapping into that,' she said.
Tigerlily believes the key to a successful relaunch will be offering its unique design and quality garments at the right price, as Australians continue to battle through cost of living pressures.
'Quality is king,' Ms Slocombe told NewsWire.
'You could see a bikini on the beach and you knew it was Tigerlily and not every brand has that.
'All our garments have beautifully finished details, metal badging, metal trims, gorgeous hardware, blanket stitching, patchwork prints, that's what we are known for and the learnings from the past are we need to retain those parts of the brand.'
Tigerlily was founded in 2000 by model, fashion designer and television personality Jodhi Meares.
Tigerlily's relaunch comes 25 years after it was first created. Picture Supplied.
Ms Slocombe said the business coming back 25 years after the brand Ms Meares built couldn't be better timing.
'We very luckily came back at the ... 25th anniversary, so having that nice milestone feels like a nice time to relaunch,' she said.
'Also boho is trending right now, so combined it feels like the stars have aligned for us.'
Ms Slocombe said the Australian fashion industry as a whole is on the rebound following a leaner time during Covid.
'There is something nice about being able to celebrate the heritage brands of Australian fashion and they are still in demand,' she said.
'It shows if you're a strong brand that stays true to its customers and knows its space then brands can really stand the test of time.
Iconic Australian retailer Tigerlily will make its return under Seafolly group.
The relaunch follows a turbulent few years for the fashion brand.
First launched in 2000 on the shores of Bondi Beach the brand quickly grew before being bought by fellow Australian fashion label Billabong in 2017.
Ten years later Tigerlily changed hands again when Crescent Capital Partners bought it out for $60m.
Tigerlily faced significant hurdles, ultimately collapsing in March 2020 as the Covid-19 pandemic severely impacted the global retail and fashion sectors.
In 2021, the business moved to eco-friendly fabrics including organic materials and natural fibres.
While the brand briefly restructured post-Covid, it again fell into financial difficulties and ultimately stopped trading in early 2024.
Prior to collapsing, Tigerlily operated 10 stores and had 40 wholesale partners in Australia and the US as well as an online presence.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month
ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month

News.com.au

time16 minutes ago

  • News.com.au

ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US subject to CLIA waiver Clever Culture Systems rose 81.3% in July on news global pharmaceutical giant Novo Nordisk purchased one of its flagship APAS Independence instruments for evaluation The healthcare sector rose 9.05% in July to be the best of the 11 ASX sectors. A turn up for the books to be sure. While remaining the worst performing sector YTD – up just 1.81% – the S&P ASX Health Care index was in recovery mode in July. The sector was buoyed by a roughly 13% rise in its biggest name blood products giant CSL (ASX:CSL), which drives much of the index. Morgans' healthcare analyst Iain Wilkie said there appeared to be a strong sector rotation on the ASX in July. "During July there certainly was a rotation out of usual strong sectors like financials and more into healthcare and the miners," he told Stockhead. "Healthcare has been beaten down for quite a long while now and is starting to look attractive. "I don't think there was anything specific in terms of a catalyst to drive the rotation." Looking ahead, Wilkie noted the sector may face continued pressure with US President Donald Trump again threatening tariffs " at a very, very, high rate, like 200%" on imported pharmaceuticals. "Trump has again thrown his weight around but until it actually hits we'll see," Wilkie said. He said US tariffs shouldn't affect companies like CSL, which is one of the world's largest manufacturers of plasma products. "Although the US collects over 60% of the world's plasma, it lacks sufficient domestic capacity to process it into finished therapies," he said. "As a result, imported plasma products are critical to meeting national demand. "Introducing tariffs on these products would likely be counterproductive as they wouldn't foster viable domestic alternatives and could drive up costs, potentially limiting patient access and causing harm." How ASX biotechs performed in July CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP PAB Patrys Limited $ 0.002 181.8% 6.9 LDX Lumos Diagnostics $ 0.073 170.4% 55.4 NSB Neuroscientific $ 0.235 170.1% 79.8 NXS Next Science Limited $ 0.140 109.0% 41.7 NOX Noxopharm Limited $ 0.110 103.7% 30.7 CMB Cambium Bio Limited $ 0.425 102.4% 8.2 DVL Dorsavi Ltd $ 0.028 86.7% 27.3 ICR Intelicare Holdings $ 0.013 85.7% 6.3 CC5 Clever Culture $ 0.029 81.3% 56.9 EMD Emyria Limited $ 0.049 75.0% 28.1 CU6 Clarity Pharma $ 4.370 74.8% 1,471.5 HMD Heramed Limited $ 0.012 71.4% 10.5 MX1 Micro-X Limited $ 0.083 69.4% 54.0 TTX Tetratherix Limited $ 5.020 66.2% 131.7 CAN Cann Group Ltd $ 0.016 60.0% 9.8 NYR Nyrada Inc. $ 0.370 54.2% 77.8 VBS Vectus Biosystems $ 0.06 50.0% 3.2 CSX Cleanspace Holdings $ 0.760 46.2% 59.5 MSB Mesoblast Limited $ 2.380 43.8% 3,046.3 AVE Avecho Biotech Ltd $ 0.005 42.9% 15.9 HIQ Hitiq Limited $ 0.020 42.9% 9.9 AYA Artryalimited $ 1.025 42.4% 116.7 ANR Anatara Ls Ltd $ 0.007 40.0% 1.5 ATH Alterity Therap Ltd $ 0.014 40.0% 128.9 CBL Control Bionics $ 0.040 37.9% 12.1 EYE Nova EYE Medical Ltd $ 0.150 36.4% 41.2 IBX Imagion Biosys Ltd $ 0.015 36.4% 3.0 IPD Impedimed Limited $ 0.047 34.3% 93.4 RCE Recce Pharmaceutical $ 0.388 33.6% 108.4 NTI Neurotech Intl $ 0.020 33.3% 21.0 VFX Visionflex Group Ltd $ 0.00 33.3% 6.7 AT1 Atomo Diagnostics $ 0.018 28.6% 14.2 AHC Austco Healthcare $ 0.370 27.6% 137.0 TRP Tissue Repair $ 0.240 26.3% 14.5 SOM SomnoMed Limited $ 0.815 25.4% 171.8 1AD Adalta Limited $ 0.003 25.0% 2.8 ADR Adherium Ltd $ 0.005 25.0% 9.0 BIT Biotron Limited $ 0.003 25.0% 3.3 CUV Clinuvel Pharmaceut. $ 12.970 25.0% 617.5 FRE Firebrickpharma $ 0.077 24.2% 17.5 CMP Compumedics Limited $ 0.315 23.5% 66.3 NEU Neuren Pharmaceut. $ 17.290 22.5% 2,150.6 ILA Island Pharma $ 0.170 21.4% 40.8 ATX Amplia Therapeutics $ 0.240 20.0% 111.9 DOC Doctor Care Anywhere $ 0.125 19.0% 47.7 EBR EBR Systems $ 1.410 18.0% 514.6 LTP Ltr Pharma Limited $ 0.340 17.2% 60.6 PAR Paradigm Bio. $ 0.355 16.4% 136.1 LGP Little Green Pharma $ 0.115 16.2% 35.1 M7T Mach7 Tech Limited $ 0.380 15.2% 89.3 ALC Alcidion Group Ltd $ 0.115 15.0% 154.4 NC6 Nanollose Limited $ 0.077 14.9% 24.1 CYC Cyclopharm Limited $ 1.040 14.3% 113.4 SPL Starpharma Holdings $ 0.100 13.6% 43.9 MVF Monash IVF Group Ltd $ 0.800 13.5% 309.8 SNT Syntara Limited $ 0.060 13.2% 97.6 CSL CSL Limited $ 270.900 13.1% 128,514.7 PME Pro Medicus Limited $ 321.890 12.9% 33,058.3 CVB Curvebeam Ai Limited $ 0.080 12.7% 33.2 IMM Immutep Ltd $ 0.270 12.5% 385.3 MVP Medical Developments $ 0.610 11.9% 64.8 TRJ Trajan Group Holding $ 0.800 11.9% 121.9 GLH Global Health Ltd $ 0.076 11.8% 4.5 VIT Vitura Health Ltd $ 0.07 11.3% 47.0 PIQ Proteomics Int Lab $ 0.360 10.8% 57.3 IRX Inhalerx Limited $ 0.042 10.5% 9.0 IDT IDT Australia Ltd $ 0.098 10.1% 40.7 NUZ Neurizon Therapeutic $ 0.170 9.7% 81.2 PGC Paragon Care Limited $ 0.400 9.6% 653.8 RHY Rhythm Biosciences $ 0.059 9.3% 17.4 1AI Algorae Pharma $ 0.006 9.1% 10.1 CTQ Careteq Limited $ 0.012 9.1% 2.8 AHX Apiam Animal Health $ 0.565 8.7% 103.0 ARX Aroa Biosurgery $ 0.630 8.6% 224.3 OCC Orthocell Limited $ 1.275 8.5% 309.7 MAP Microbalifesciences $ 0.092 8.2% 47.4 PSQ Pacific Smiles Grp $ 1.670 8.1% 269.9 PNV Polynovo Limited $ 1.290 7.9% 858.4 RMD ResMed Inc. $ 42.450 7.9% 61,930.3 PTX Prescient Ltd $ 0.047 6.8% 38.7 REG Regis Healthcare Ltd $ 8.370 6.8% 2,545.6 TYP Tryptamine Ltd $ 0.03 6.7% 44.6 SDI SDI Limited $ 0.883 6.3% 104.6 COH Cochlear Limited $ 318.520 6.0% 20,541.2 RHC Ramsay Health Care $ 38.770 5.7% 8,808.5 IDX Integral Diagnostics $ 2.670 5.1% 1,001.8 IMC Immuron Limited $ 0.064 4.9% 16.9 OCA Oceania Healthc Ltd $ 0.660 4.8% 461.5 EBO Ebos Group Ltd $ 37.250 4.7% 7,552.6 RAD Radiopharm $ 0.023 4.5% 54.4 ACW Actinogen Medical $ 0.024 4.3% 76.3 IIQ Inoviq Ltd $ 0.385 4.1% 43.5 AGH Althea Group $ 0.026 4.0% 21.4 IME Imexhs Limited $ 0.300 3.4% 15.8 CYP Cynata Therapeutics $ 0.155 3.3% 37.3 SHL Sonic Healthcare $ 27.610 3.1% 13,532.2 FPH Fisher & Paykel H. $ 34.090 1.4% 19,481.0 CTE Cryosite Limited $ 0.750 0.7% 36.6 VLS Vita Life Sciences.. $ 2.26 0.4% 124.4 ACR Acrux Limited $ 0.016 0.0% 7.0 BP8 Bph Global Ltd $ 0.002 0.0% 2.1 EMV Emvision Medical $ 1.740 0.0% 150.1 EOF Ecofibre Limited $ 0.020 0.0% 7.6 EPN Epsilon Healthcare $ 0.024 0.0% 7.2 NAN Nanosonics Limited $ 4.050 0.0% 1,196.3 OSX Osteopore Limited $ 0.011 0.0% 2.6 TD1 Tali Digital Limited $ 0.001 0.0% 4.2 TRI Trivarx Ltd $ 0.008 0.0% 5.0 TRU Truscreen $ 0.016 0.0% 12.3 ACL Au Clinical Labs $ 2.760 -0.7% 536.1 CGS Cogstate Ltd $ 1.730 -0.9% 292.9 MYX Mayne Pharma Ltd $ 4.950 -1.0% 405.4 ANN Ansell Limited $ 29.950 -1.1% 4,410.5 AFP Aft Pharmaceuticals $ 2.400 -1.2% 259.6 RGT Argent Biopharma Ltd $ 0.080 -1.2% 4.7 RAC Race Oncology Ltd $ 1.160 -1.3% 198.9 SNZ Summerset Grp Hldgs $ 10.300 -1.3% 2,513.8 HLS Healius $ 0.770 -1.9% 548.2 ALA Arovella Therapeutic $ 0.098 -2.0% 117.7 BMT Beamtree Holdings $ 0.245 -2.0% 72.6 ONE Oneview Healthcare $ 0.245 -2.0% 185.7 4DX 4Dmedical Limited $ 0.235 -2.1% 136.2 COV Cleo Diagnostics $ 0.380 -2.6% 48.8 RHT Resonance Health $ 0.038 -2.6% 17.5 AVH Avita Medical $ 1.670 -2.6% 217.6 SIG Sigma Health Ltd $ 2.890 -3.3% 32,726.4 PYC PYC Therapeutics $ 1.240 -4.2% 729.1 IXC Invex Ther $ 0.085 -4.5% 6.9 OIL Optiscan Imaging $ 0.105 -4.5% 87.7 ZLD Zelira Therapeutics $ 0.41 -6.8% 4.9 MDR Medadvisor Limited $ 0.075 -7.4% 43.8 BDX Bcaldiagnostics $ 0.058 -7.9% 20.5 GSS Genetic Signatures $ 0.330 -9.6% 76.1 CDX Cardiex Limited $ 0.036 -10.0% 18.7 PER Percheron $ 0.009 -10.0% 10.9 AGN Argenica $ 0.680 -10.5% 86.1 OSL Oncosil Medical $ 1.070 -10.8% 20.2 ECS ECS Botanics Holding $ 0.008 -11.1% 11.0 PEB Pacific Edge $ 0.085 -11.5% 75.9 IVX Invion Ltd $ 0.096 -12.7% 8.2 EZZ EZZ Life Science $ 2.030 -13.2% 99.1 TLX Telix Pharmaceutical $ 21.050 -13.8% 6,991.3 AVR Anteris Technologies $ 5.130 -16.4% 179.8 DXB Dimerix Ltd $ 0.470 -18.3% 285.1 SHG Singular Health $ 0.300 -18.9% 93.5 IMR Imricor Med Sys $ 1.225 -19.4% 324.2 MEM Memphasys Ltd $ 0.004 -20.0% 7.9 PCK Painchek Ltd $ 0.035 -22.2% 66.3 CHM Chimeric Therapeutic $ 0.003 -25.0% 11.4 VHL Vitasora Health Ltd $ 0.03 -28.2% 46.4 UCM Uscom Limited $ 0.01 -31.3% 2.9 UBI Universal Biosensors $ 0.02 -31.4% 7.2 IMU Imugene Limited $ 0.270 -38.9% 77.2 BOT Botanix Pharma Ltd $ 0.150 -53.1% 289.3 Patrys (ASX:PAB) rose ~182% in July after announcing a solid June quarter including a board restructure, $300,000 capital raise and actively pursuing partnering and licensing opportunities for both of its oncological cell therapy deoxymab assets. In July Patrys also announced a fully underwritten, pro-rata non-renounceable entitlement offer of three fully paid ordinary shares for every four shares held at an issue price of $0.001 per Share, together with on free-attaching new share for every four shares applied for and issued, to raise up to ~$1.78m. Lumos Diagnostics (ASX:LDX) rose more than 170% in July after l anding a landmark six-year distributor deal worth hundreds of millions of dollars to sell its rapid point-of-care diagnostic FebriDx in the US market. The FebriDx product is a simple test able to differentiate between bacterial and non-bacterial acute respiratory infections. The lucrative US licensing deal with Hong-Kong based PHASE Scientific could see Lumos net up to to US$317m (~A$487m), and has been described as one of the largest distribution deals of its type to be done by an ASX-listed point-of-care diagnostics company. Adelaide-based Clever Culture Systems (ASX:CC5), rose 81.3% in July after announcing global pharmaceutical giant Novo Nordisk had purchased one of its flagship APAS Independence instruments for evaluation. The machine will be delivered to Novo's central team in Denmark, where it will undergo a full-scale evaluation to assess its suitability for deployment across Novo's global manufacturing network. The APAS Independence uses AI technology to automate one of the most time-consuming parts of microbiology, analysing agar plates for contamination. Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) was up 74.8% in July after completing a large $203m institutional placement at a 15% premium to the company's 15-day average price, to fund their clinical program. Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company". 'I have never done a deal that fast,' Taylor said. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group .' At Stockhead, we tell it like it is. While Lumos Diagnostics and Clever Culture Systems are Stockhead advertisers, the companies did not sponsor this article. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.

NRL must act as expansion team faces impending doom
NRL must act as expansion team faces impending doom

News.com.au

time27 minutes ago

  • News.com.au

NRL must act as expansion team faces impending doom

The champagne has barely had time to go flat since the Bears were triumphantly reinstated and it already looks like they'll need to merge with Manly again. Yes, it's been a glorious honeymoon for the black-and-red diehards since the Perth franchise was welcomed as the NRL's newest entity. But sadly all the talk of dream signings and fantasy XIII's have now been swamped with the jarring realisation that assembling an actual NRL squad within 18 months might be a bigger b*stard than first expected. Even though the club can't approach any contracted players until after November 1st, already there are massive concerns piling up about the monstrous task ahead. Let's remember this is a franchise building from a standing start with nothing more than a history, a logo and a Florimo. Plus there's the stress of launching the project against a timeframe that's like packing a scrum with a five second shot clock and six wingers. Further to that, they're humbly entering an AFL stronghold policed by Kerry Stokes' media monopoly, meaning they'll cop stones from the moment they disembark the plane let alone if they start the season like a cold Toyota Cressida. But of greatest concern is the squad building exercise, mainly because the Bears will be fishing in a parched player market of catfish, dregs and expensive teases. Add the Papua New Guinea franchise soon to be feeding from the same pool, and coach Mal Meninga's biggest issue could be getting himself fit enough again to play in the centres. Sure, nobody claimed it would be a cinch convincing 30 blokes to relocate across the country to a timezone closer to Jakarta than Sydney. But the challenges were never a secret, and that's why there's one major stakeholder in this arrangement that's dropped its lollies. Peter V'landys and the ARLC should be fiercely applauded for reintroducing the Bears back to rugby league and for gifting Western Australia the team it deserves. But after months of subluxing their shoulders patting themselves on the back, it's time they threw genuine support behind the new licence that isn't just standing at press conferences throwing shade at the AFL. As we know, the PNG licence will be reportedly armed with a festoon of salary cap exemptions relating to tax free salaries and relocation costs, whereas the only exemption the Bears have thus far is from good players and hope. If V'Landys is serious about the Perth club being 'competitive in the first year' then he needs to wake up and afford the Bears the same licence to spend with abandon. And if he doesn't, the club is doomed before it even starts. Without help, the Bears franchise will serve its formative years abused by AFL narks and sneaky player agents bumping up their client's asking price. Already we've seen blue chip prospects dropping off by the day for the fledging franchise, with Kalyn Ponga, Jahrome Hughes and Api Koroisau the latest ruled out after restating their commitment to Eastern Standard Time. This has left so little to get excited about that attention has turned to star targets in Cameron Munster and Tino Fa'asuamaleaui even though both are contracted for 2027. Undoubtedly these blokes are needle-moving names who'd cost the farm for any club. But with the mooted Bear Tax applied to their already-exorbitant asking price, their cost to relocate West is already being speculated to cost upwards of $2m a season. And while we'd all love a Tino in the middle or a Munny on a 10 hour round trip flight once a fortnight, if the Bears are forced to stump up the figures discussed within the NRL's current salary cap of $11.8m they'll barely have enough left over for a bench. Here's where the NRL needs to stop being a tightarse by padding out the Bears salary cap with more support and extra zeros. Allow the Perth club 15% on top of the agreed figure and bolster this with some kinda special access to local juniors, ie Penrith's. Then pick up the bill for any relocation costs and flak jackets required when the squad is first smuggled in to town past Perth's Channel Seven bureau. Then to keep these far-flung heroes happy despite being five hours away surrounded by West Coast Eagles fans and bikies, the NRL needs to legislate the Bears access to ceiling-free third party agreements. As we know, statistics allege that Perth's population currently stands at 87% mining magnates. And while many have their revenue tied up in AFL, it means with some gentle convincing there could be an NRL franchise backed by the most powerful person in Australia, and it wouldn't be PNG and Anthony Albanese. With help from the NRL, the Bears could jump in bed with Gina Rinehart and access that sweet mining cabbage so they can fish in the player market with dynamite.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store